Angany entered a partnering agreement to evaluate the safety and efficacy of the French-Canadian pharmaceutical company’s lead peanut allergy biological candidate BP/AH-01 with the Food Allergy Center at Massachusetts General Hospital and MassGeneral Hospital for Children.

Three new conditions reported by a small number of people after vaccination with Covid-19 shots from Pfizer and Moderna are being studied to assess if they may be possible side effects, Europe’s drugs regulator said on Aug. 11.

Pfizer Inc. agreed to pay $345 million to resolve claims by consumers who claim they overpaid for EpiPens due to anticompetitive and unfair practices by the drugmaker and the company that markets the emergency allergy treatment, Mylan.

Idorsia is launching a late-stage trial of the experimental heart-attack drug selatogrel that the Swiss company hopes will become what it describes as akin to an “EpiPen” for people at risk of acute myocardial infarction (AMI).

The U.S. Centers for Disease Control and Prevention is observing a lower rate of severe allergic reactions in people in the United States who have received Pfizer Inc. and BioNTech SE’s Covid-19 vaccine.

Severe allergic reactions to Moderna Inc.’s coronavirus vaccine appear to be quite rare, the U.S. Centers for Disease Control and Prevention (CDC) said, after more than 4 million people received their first dose.

Moderna Inc. received a report from California’s health department that several people at a center in San Diego were treated for possible allergic reactions to the company’s Covid-19 vaccine from a particular batch.

DBV Technologies unveiled a global restructuring plan that will result in a reduction of more than 200 jobs.

BioSpace reviewed the top 10 novel drug approvals of 2020, loosely based on projected earnings in the upcoming years.

The European Commission approved Aimmune Therapeutics Inc.’s Palforzia for the treatment of peanut allergy.